



# The Innovative Medicines Initiative (IMI)

---

## Call & Evaluation Process

March 27<sup>th</sup>, 2008



# Agenda



- 
- Participation & Funding
  - Call & Evaluation Process

# IMI Call Process is Different from the 7<sup>th</sup> Framework Programme Process

---



1. Research Topics are approved by the IMI Governing Board (EFPIA and European Commission) based on a proposal from EFPIA Research Directors Group.
2. The private consortium is established by the EFPIA Research Directors Group
3. The public consortium submits an Expression of Interest without involving the private consortium
4. The public-private consortium is established at the stage 1 of the peer review process.

# Rules for Participation in IMI Consortium



- Independent legal entities
- Capacities to carry out work themselves
- Research performed in Europe or country associated with the 7th framework programme
- At least 2 EFPIA legal entities and 2 non-EFPIA legal entities per project

# Eligibility for IMI funding



<b>Eligible for funding</b>	<b>Non-eligible for funding</b>
<ul style="list-style-type: none"><li>– Academia</li><li>– SMEs (EU definition)</li><li>– Patient Organisations</li><li>– Other non-for-profit legal entities</li></ul>	<ul style="list-style-type: none"><li>– EFPIA companies</li><li>– Other companies not falling within the EU definition of SMEs</li></ul>

# Funding is according to EU State Aid Rules



## **Project Costs Calculation:**

100% of direct costs + overheads (= 20% of direct costs minus subcontracting)

Reimbursement

In-kind contribution

## **Applicant Eligible for Funding**

### **Re-imbusement Calculation:**


75% of costs of research activities  
100% of costs of management activities

## **EFPIA Companies**

### **Calculation of in-kind contribution:**

Project Costs Calculation


# Funding of Research Projects



Funding will be allocated to IMI projects until 2013 but research will be supported until 2017




**Total Annual Budget**



- 
- Participation & Funding
  - Call & Evaluation Process

# Call & Evaluation Process Overview



# Call & Evaluation Process

## Call definition

---



Call definition

# Description of the Call Topics (1)



1. Title
2. Project description
3. Key deliverables of the project
4. EFPIA participants in the projects
5. Role of EFPIA participants in the projects
6. Duration of the project
7. Contribution from the EFPIA Companies
8. Expectations from the Applicant Consortium

## Description of the Call Topics (2)



- IMI research projects will often be multi disciplinary and addressing translation medicine challenges. Integrated approaches between non-clinical and clinical disciplines are often required.
- The successful Applicant Consortium is expected to include expertise for all aspects of the areas mentioned in the description of the call topics.

# Call & Evaluation Process

## Stage 1



# Description of the Expression of Interest



1. Composition of the public consortium
2. Abstract (1/2 pages)
3. Science (3 pages)
4. Knowledge Management (1/2 page)
5. Training and Education (1/2 page)
6. Outstanding issues (1/2 page)
7. Budget plan (1/2 page)

**Written by the Applicant Consortium:  
i.e. academia, SMEs, regulators, patients organisations  
(without pharmaceutical companies)**


# Peer Review Stage 1



- **Peer Review Committees**
  - One Standing Peer Review Committee per Pillar of the Strategic Research Agenda
  - Assisted by ad hoc experts relevant to the call topics
  - EFPIA Consortia members participate in evaluation of Expressions of Interest
- **Responsibility**
  - To evaluate science of Expressions of Interest
- **Composition**
  - Members reflecting a balance of public-private research expertise
- **Decision Making**
  - By consensus between all experts

# Call & Evaluation Process

## Stage 2



# Description of the Full Project Proposal



- Written jointly by the EFPIA Consortium and Applicant Consortium members
- Full description of research activities
  - Who, when, and how much
- Will need a draft Project Agreement before submission
  - IPR sharing agreed between all partners


**Written by the Public Private Consortium:  
i.e. academia, SMEs, regulators, patients organisations  
and pharmaceutical companies**

# Peer Review Stage 2



- **Peer Review Committees**
  - One Standing Peer Review Committee per Pillar of the Strategic Research Agenda
  - Assisted by ad hoc experts relevant to the call topics
  - No EFPIA Consortia members
- **Responsibility**
  - To evaluate Full Proposals based on science and feasibility
- **Composition**
  - Members reflecting a balance of public-private research expertise
- **Decision Making**
  - By consensus between all experts

# Call & Evaluation Process



# Objectives



---

April 2008:	Publication of the IMI Call
July 2008:	Deadline for Expression of Interest
November 2008:	Deadline for Full Project Proposal
December 2008:	Deadline for selection
February 2009:	Signature of Grant Agreement
March 2009:	Start of research project